Andro significantly reduced tumor volume and tumor weights in a breast cancer xenograft model, and that the expression of COX-2 in transplanted tumors was significantly reduced in the treatment group as the dose of Andro increased47. This evidence concerns the gene PTGS2 and breast carcinoma.